2014
Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia
Chen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell C, Paietta E, Willman C, Carroll W, Melnick A, Jung J, Jumaa H, Coligan J, Bolland S, Mak T, Muschen M. Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. Blood 2014, 124: 792. DOI: 10.1182/blood.v124.21.792.792.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaTyrosine kinase inhibitorsB cell receptorInhibitory receptorsTherapeutic targetPre-BCR signalingLymphoblastic leukemiaXenograft cellsB cellsSurvival rateB-cell acute lymphoblastic leukemiaCell deathAuto-reactive clonesFree survival rateCell acute lymphoblastic leukemiaOverall survival rateWorse clinical outcomesLeukemia cellsNegative B cell selectionAdditional therapeutic targetsAvailable therapeutic interventionsG1cell cycle arrestPotent tyrosine kinase inhibitorNovel small molecule inhibitorColony formation capacity
2010
Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin
Jiang E, Park E, Nguyen C, Yoon J, Hsieh Y, Loh M, Muschen M, Kahn M, Kim Y. Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin. Blood 2010, 116: 3264. DOI: 10.1182/blood.v116.21.3264.3264.Peer-Reviewed Original ResearchICG-001 treatmentMedian survival timeICG-001Β-cateninΓ-cateninDose-dependent downregulationSaline control groupAcute lymphoblastic leukemiaSmall molecule specific inhibitorNOD/SCIDReduction of survivinΒ-catenin siRNAReal-time RT-PCRDownregulation of survivinΒ-catenin expressionDecrease of survivinOvercoming Drug ResistanceTime RT-PCRWestern blot analysisPoor prognosisLymphoblastic leukemiaColon cancer cellsSurvival timeShRNA controlXenograft cells